USFDA

Indian drugmaker Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration to market Lamotrigine orally disintegrating tablets in the United States. The authorization covers multiple strengths under the abbreviated new drug application pathway, confirming therapeutic equivalence to the reference listed drug, Lamictal, marketed by GlaxoSmithKline LLC. 

Indian pharmaceutical major Lupin Limited has received approval from the U.S. Food and Drug Administration for its generic version of a widely prescribed anti-seizure medication, reinforcing its strategic focus on complex generics in the United States. The regulatory clearance enables the company to market the product in the world’s largest pharmaceutical market, where demand for cost-effective neurological therapies remains robust. The approval is expected to bolster Lupin’s U.S. revenues and enhance its competitive positioning.

Piramal Pharma has received a Form 483 from the United States Food and Drug Administration following an inspection of one of its manufacturing facilities. The regulatory document outlines specific observations related to procedural or compliance gaps that require corrective action. While a Form 483 does not constitute a final regulatory action or import restriction, it signals areas where the company must strengthen quality systems and documentation practices. Piramal Pharma stated it will respond within the stipulated timeline and implement necessary remediation measures.

Natco Pharma has received approval from the United States Food and Drug Administration (USFDA) for its latest oncology drug, marking a significant milestone in the company’s global expansion strategy. The approval not only underscores Natco’s research and development capabilities but also enhances access to cutting-edge cancer therapies in international markets. Industry experts note that the USFDA nod opens a substantial revenue stream for the Hyderabad-based firm while reinforcing India’s position in the global pharmaceutical landscape.

Indian pharmaceutical major Zydus has secured approval from the US Food and Drug Administration for its latest diabetes treatment — a significant achievement that positions the company as a stronger contender in the global diabetes-care market. The green light from the US regulator validates the safety and efficacy profile of the drug and paves the way for its launch in the lucrative United States market. For Zydus, this approval represents not only a commercial breakthrough, but also a validation of its research and development capabilities.

Pharmaceutical major Lupin has achieved a significant milestone by securing approval from the U.S. Food and Drug Administration (USFDA) for its generic version of a widely used HIV treatment. This regulatory clearance underscores Lupin’s growing footprint in the U.S. market, offering an affordable alternative to branded antiretroviral therapies. The approval is expected to strengthen the company’s revenue streams, expand patient access to critical medications, and enhance its position in the competitive generics landscape.

Caplin Point Laboratories has received approval from the United States Food and Drug Administration (USFDA) for its Milrinone injection, a cardiovascular drug used in the management of heart failure and related conditions. The approval allows the Indian pharmaceutical firm to market the therapy in the U.S., a key market for high-value generic injectables. This milestone strengthens Caplin Point’s presence in the cardiovascular segment while showcasing its ability to meet stringent regulatory standards.

Indian pharmaceutical giant Lupin has secured approval from the United States Food and Drug Administration (USFDA) for its generic Risperidone injection, a widely used treatment for schizophrenia and bipolar disorder. The approval allows Lupin to market the injectable formulation in the U.S., one of the world’s largest pharmaceutical markets. This regulatory milestone strengthens Lupin’s central nervous system (CNS) portfolio, expands its footprint in high-value generics, and demonstrates its capability to meet stringent international compliance standards.

Indian pharmaceutical major Glenmark Pharmaceuticals has received critical observations from the United States Food and Drug Administration (USFDA) following an inspection of its Baddi facility in Himachal Pradesh. The US regulator, after a routine audit, identified multiple lapses in the plant’s manufacturing practices, issuing a Form 483 with seven key observations. While the company has yet to receive any import restrictions or warning letters, the findings underscore the growing scrutiny faced by Indian drugmakers exporting to the United States.